MyVisionTest News Archive
News Tag Cloud
accessibility AMD Amsler grid animal study antioxidants AREDS Austrailia automobile Avastin bionic eye blindness CABERNET Canada CAPT CATT CD59 cell phone clinical trial CNV combo therapy complement computers CRVO CSCR depression diabetes diet drug delivery dry AMD ECT employment endophthalmitis eye drops fish Foresee PHP fundus autofluorescence genetics GPS ICGA integrin internet Japan lipofuscin low vision Lucentis lutein Macugen macular edema mobility myopia NHS NICE OCT PCV PDT PED photography PHP POT-4 PrONTO racial differences radiation radio reading skills retinitis pigmentosa retinylamine RNA interference S1P spirituality steroid student sunlight telescope television traffic safety travel UK vasohibin VEGF VEGF Trap vision test visual cycle visual prosthesis vitreous wet AMDMore tags...
Recent News Stories
Measuring vision recovery following Avastin therapy
Dec 1, 2008
A new study finds that optical coherence tomography (OCT) subretinal fluid measurements correleted well with visual acuity recovery following Avastin therapy for neovascular age-related macular degeneration (AMD). The advent of high-definition "spectral... Read more...
A new study finds that optical coherence tomography (OCT) subretinal fluid measurements correleted well with visual acuity recovery following Avastin therapy for neovascular age-related macular degeneration (AMD). The advent of high-definition "spectral... Read more...
Retinylamine Slows Progression of AMD-Like Condition in Mice
Nov 23, 2008
An investigational drug called retinylamine slowed the progression of a condition in mice that is very similar to age-related macular degeneration (AMD) in humans. The AMD-like condition was triggered in mice by disrupting the removal of all-trans-retinal from the retina.... Read more...
An investigational drug called retinylamine slowed the progression of a condition in mice that is very similar to age-related macular degeneration (AMD) in humans. The AMD-like condition was triggered in mice by disrupting the removal of all-trans-retinal from the retina.... Read more...
Meta-analysis confirms Lucentis safety
Nov 23, 2008
Lucentis (ranibizumab) appears safe in the treatment of wet age-related macular degeneration (AMD), according to an analysis of 4 large clinical trials. Dr David Boyer presented these findings at the 2008 Joint Meeting of the American Academy of Ophthalmology (AAO) and the European Society of... Read more...
Lucentis (ranibizumab) appears safe in the treatment of wet age-related macular degeneration (AMD), according to an analysis of 4 large clinical trials. Dr David Boyer presented these findings at the 2008 Joint Meeting of the American Academy of Ophthalmology (AAO) and the European Society of... Read more...
Fewer injections for wet AMD: Clinical trial update
Nov 23, 2008
Medscape has assembled updates on several ongoing clinical trials into new drugs and dosing strategies that were presented at the 2008 Joint Meeting of the American Academy of Ophthalmology and the European Society of Ophthalmology held in November. Below is a synopsis of... Read more...
Medscape has assembled updates on several ongoing clinical trials into new drugs and dosing strategies that were presented at the 2008 Joint Meeting of the American Academy of Ophthalmology and the European Society of Ophthalmology held in November. Below is a synopsis of... Read more...
Role of integrins in proliferative diabetic retinopathy
Nov 22, 2008
This article investigates the role of integrins in proliferative diabetic retinopathy, and concludes that they represent a potential target for the development of new drug therapies for the disease. Integrins have also been identified as playing a role in the pathogenesis of choroidal... Read more...
This article investigates the role of integrins in proliferative diabetic retinopathy, and concludes that they represent a potential target for the development of new drug therapies for the disease. Integrins have also been identified as playing a role in the pathogenesis of choroidal... Read more...
Simultaneous fluorescein angiography and indocyanine green angiography detects polypoidal choroidal vasculopathy
Nov 22, 2008
A new study illustrates the value of simultaneous fluorescein angiography (FA) and indocyanine green angiography (ICGA) in detecting patients with polypoidal choroidal vasculopathy (PCV). PCV is a distinct clinical entity... Read more...
A new study illustrates the value of simultaneous fluorescein angiography (FA) and indocyanine green angiography (ICGA) in detecting patients with polypoidal choroidal vasculopathy (PCV). PCV is a distinct clinical entity... Read more...
Florida drivers vision test results in fewer auto accidents
Nov 21, 2008
A Florida vision screening law targeting older drivers appears to be associated with a decrease in death rates despite little existing evidence linking vision and car crashes. A report in this month's issue of Archives of Ophthalmology highlights the January 2004 law... Read more...
A Florida vision screening law targeting older drivers appears to be associated with a decrease in death rates despite little existing evidence linking vision and car crashes. A report in this month's issue of Archives of Ophthalmology highlights the January 2004 law... Read more...
Ophthotech initiates phase 1 trials for two AMD drugs
Nov 21, 2008
Ophthotech has recently announced the initiation of two phase 1 clinical trials for new drugs designed to treat age-related macular degeration (AMD). One drug is an anti-C5 complement factor aptamer known as ARC1905. The second drug is a monoclonal antibody... Read more...
Ophthotech has recently announced the initiation of two phase 1 clinical trials for new drugs designed to treat age-related macular degeration (AMD). One drug is an anti-C5 complement factor aptamer known as ARC1905. The second drug is a monoclonal antibody... Read more...
Othera receives patent for topical drug for dry AMD
Nov 21, 2008
The U.S. Patent and Trademark Office has issued Othera Pharmaceuticals the first patent covering a broad class of disubstituted hydroxylamine small molecules that target oxidative stress and inflammation involved in age-related macular degeneration and other ocular disorders. U.S. Patent No. 7... Read more...
The U.S. Patent and Trademark Office has issued Othera Pharmaceuticals the first patent covering a broad class of disubstituted hydroxylamine small molecules that target oxidative stress and inflammation involved in age-related macular degeneration and other ocular disorders. U.S. Patent No. 7... Read more...
Enabling The Blind To Find Their Way
Nov 21, 2008
"Eyes on the future" is the mantra of the 'World Sight Day' held in October to raise awareness of blindness and vision impairment. New technologies, developed by European researchers offering the visually impaired greater independence, live up to this vision. Many of the most... Read more...
"Eyes on the future" is the mantra of the 'World Sight Day' held in October to raise awareness of blindness and vision impairment. New technologies, developed by European researchers offering the visually impaired greater independence, live up to this vision. Many of the most... Read more...
Steroids protect photoreceptors after photodynamic therapy
Nov 20, 2008
A study of photodynamic therapy (PDT) in laboratory rats has found that use of steroids 1 hour before the procedure reduced photoreceptor death and improved CNV resolution 1 week after PDT. Combining PDT with steroids has been found to improve the visual outcome of the procedure, although those <... Read more...
A study of photodynamic therapy (PDT) in laboratory rats has found that use of steroids 1 hour before the procedure reduced photoreceptor death and improved CNV resolution 1 week after PDT. Combining PDT with steroids has been found to improve the visual outcome of the procedure, although those <... Read more...
Somatostatin receptor agonists inhibit retinal and choroidal neovascularization
Nov 19, 2008
A new study reports that the somatostatin analogue RFE-011 effectively inhibited retinal and choroidal neovascularization in mice, and was able to penetrate the eye after topical administration. The presence of somatostatin receptors on tumour cells and on proliferating vascular... Read more...
A new study reports that the somatostatin analogue RFE-011 effectively inhibited retinal and choroidal neovascularization in mice, and was able to penetrate the eye after topical administration. The presence of somatostatin receptors on tumour cells and on proliferating vascular... Read more...
